Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Pituitary Neoplasms 7Pituitary ACTH Hypersecretion 3Acromegaly 2Recurrence 1Prostatic Neoplasms 1Prolactinoma 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Dumping Syndrome 1Brain Neoplasms 1Adrenocortical Hyperfunction 1Adenoma 1ACTH-Secreting Pituitary Adenoma 1

Interventions

3-Iodobenzylguanidine 3olaparib 1lutetium Lu 177 dotatate 1entrectinib 1entinostat 1Pemetrexed 1Paclitaxel 1Dexamethasone 1Calcium Dobesilate 1Cabergoline 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Cabergoline × Endocrine × Clear all
NCT03457389 2020-03-18

Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma

Seoul National University Hospital

Phase NA Unknown
68 enrolled
Endocrine

Pituitary Neoplasms, Recurrence, Prolactinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡